Flibanserin
SIGMA/SML0797 - ≥98% (HPLC)
Synonym: 1,3-
CAS Number: 167933-07-5
Empirical Formula (Hill Notation): C20H21F3N4O
Molecular Weight: 390.40
Linear Formula: C20H21F3N4O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C20H21F3N4O/c21-20(22, |
| InChI key | CCIZQGRSEAHATK-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | FC(F)(F)c1ccc(cc1)N2CCN(C |
| solubility | DMSO: 10 mg/mL, clear |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist. |
| Biochem/physiol Actions: | Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist. Flibanserin has high affinity for human 5-HT1A receptors (Ki = 1 nm) and lower affinity for 5-HT2A (Ki = 49 nm) and D4 (Ki = 4–24 nm) receptors, and negligible affinity for a variety of other neurotransmitter receptors and ion channels. Flibanserin was investigated as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin. Recently, Flibanserin was found to reduce L-DOPA-induced dyskinesia in a model of Parkinson′s Disease. |
| Features and Benefits: | This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H301 - H315 - H319 - H335 |
| Precautionary statements | P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | T |
| Risk Statements | 25-36/37/38 |
| Safety Statements | 26-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


